🇺🇸 FOLFIRI + bevacizumab in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Proteinuria — 2 reports (18.18%)
  2. Acne — 1 report (9.09%)
  3. Aminoaciduria — 1 report (9.09%)
  4. Anaemia — 1 report (9.09%)
  5. Blood Parathyroid Hormone Increased — 1 report (9.09%)
  6. Cholinergic Syndrome — 1 report (9.09%)
  7. Dandruff — 1 report (9.09%)
  8. Dermatitis — 1 report (9.09%)
  9. Dry Skin — 1 report (9.09%)
  10. Electrolyte Imbalance — 1 report (9.09%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is FOLFIRI + bevacizumab approved in United States?

FOLFIRI + bevacizumab does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for FOLFIRI + bevacizumab in United States?

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) is the originator. The local marketing authorisation holder may differ — check the official source linked above.